乌鸦传媒

Crystal Phend

Crystal Phend

Authors >

Crystal Phend

Crystal Phend is a contributing editor with 乌鸦传媒, where she's been covering medical news of all stripes since 2006.

Connect:

email image

Latest from Crystal Phend

A photo of a box of Sudafed PE

<乌鸦传媒>FDA Reviewers Say OTC Decongestant Doesn't Work

But they acknowledge that taking the only shelf-accessible product off the market raises issues

A photo of a woman in a wheelchair opening the driver鈥檚 door of her car.

<乌鸦传媒>Vaccines Not Linked to MS Flare-Ups

Nationwide French study might clear up a decade of doubts

ESC over a photo of Amsterdam RAI Convention Centre.

<乌鸦传媒>No Aspirin After PCI? Extended P2Y12 Monotherapy? Trials Weigh In

Two trials read out, but generalizability is the question

ESC over a photo of Amsterdam RAI Convention Centre.

<乌鸦传媒>Novel Amyloid Drug Improves Mid-Term Outcomes in ATTR Cardiomyopathy

Pivotal trial "suggests the tantalizing possibility of genuine clinical improvement"

ESC over a photo of Amsterdam RAI Convention Centre.

<乌鸦传媒>Less Atrial Pacing Doesn't Cut Afib in Sinus Node Dysfunction

Trial debunks strategy for higher-risk group

ESC over a photo of Amsterdam RAI Convention Centre.

<乌鸦传媒>Immune Suppressant Stumbles for Acute Myocarditis in Early Data

Phase II trial might not end the story for anti-inflammatory approach, though

ESC over a photo of Amsterdam RAI Convention Centre.

<乌鸦传媒>Ambulance Routing Might Not Matter After Cardiac Arrest

Trial in best-case scenario setting shows sending patients to specialty centers doesn't help

ESC over a photo of Amsterdam RAI Convention Centre.

<乌鸦传媒>Pulsed Field Ablation Measures Up in Head-to-Head Trial

Novel catheters on par with thermal ablation, but do they meet the early high hopes?

ESC over a photo of Amsterdam RAI Convention Centre.

<乌鸦传媒>Trial: ECMO Doesn't Save Lives in Cardiogenic Shock

ECLS-SHOCK trial challenges current practice, guidelines

ESC over a photo of Amsterdam RAI Convention Centre.

<乌鸦传媒>Complete PCI Better for Older MI Patients Too

Trial affirms advantage over culprit-lesion-only stenting in those ages 75 and up

鈥�

15

鈥�